Dr. Kathleen Dorris, MD
Claim this profileChildren's Hospital Colorado
Expert in Brain Tumor
Expert in Diffuse Intrinsic Pontine Glioma
28 reported clinical trials
43 drugs studied
About Kathleen Dorris, MD
Education:
- Obtained MD (Doctor of Medicine) from the University of Colorado School of Medicine in 2015.
- Completed Residency in Pediatrics at Children's Hospital Colorado in 2018.
- Finished Fellowship in Pediatric Cardiology at Children's Hospital Colorado in 2021.
Experience:
- Currently practices as a pediatric cardiologist at Children's Hospital Colorado.
- Specializes in pediatric cardiology, with comprehensive training in pediatrics.
Area of expertise
1Brain Tumor
Global LeaderStage IV
H3 K27M positive
BRAF positive
2Diffuse Intrinsic Pontine Glioma
Global LeaderH3 K27M positive
Stage IV
SST2A positive
Affiliated Hospitals
Clinical Trials Kathleen Dorris, MD is currently running
PEP-CMV Vaccine
for Pediatric Brain Tumor
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, and antibody epitopes across several haplotypes. Component A will be administered as a stable water:oil emulsion in Montanide ISA 51. Funding Source - FDA OOPD
Recruiting1 award Phase 2
Savolitinib
for Brain Tumors
This phase I trial studies the side effects and best dose of volitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory). Volitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Recruiting1 award Phase 1
More about Kathleen Dorris, MD
Clinical Trial Related1 year of experience running clinical trials · Led 28 trials as a Principal Investigator · 14 Active Clinical TrialsTreatments Kathleen Dorris, MD has experience with
- Radiation Therapy
- Tocilizumab
- INCB7839
- Alisertib
- PTC596
- Radiotherapy
Breakdown of trials Kathleen Dorris, MD has run
Brain Tumor
Diffuse Intrinsic Pontine Glioma
Glioblastoma
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kathleen Dorris, MD specialize in?
Kathleen Dorris, MD focuses on Brain Tumor and Diffuse Intrinsic Pontine Glioma. In particular, much of their work with Brain Tumor has involved Stage IV patients, or patients who are H3 K27M positive.
Is Kathleen Dorris, MD currently recruiting for clinical trials?
Yes, Kathleen Dorris, MD is currently recruiting for 14 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Kathleen Dorris, MD has studied deeply?
Yes, Kathleen Dorris, MD has studied treatments such as Radiation Therapy, Tocilizumab, INCB7839.
What is the best way to schedule an appointment with Kathleen Dorris, MD?
Apply for one of the trials that Kathleen Dorris, MD is conducting.
What is the office address of Kathleen Dorris, MD?
The office of Kathleen Dorris, MD is located at: Children's Hospital Colorado, Aurora, Colorado 80045 United States. This is the address for their practice at the Children's Hospital Colorado.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.